{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T21:48:39Z","timestamp":1744062519838},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>Worldwide, over 77\u00a0million people have been infected by human immunodeficiency virus (<jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content>) but its cure remains elusive. Once considered a fatal disease, advances in antiretroviral therapy (ART) have dramatically increased the life expectancy of infected persons. Much progress has been made in the development and utilization of combination ART and preventative pre\u2010exposure prophylaxis products, however, numerous obstacles prevent eradication. Clinical pharmacologists along with world health organizations continue to play a key role in identifying and implementing strategies to combat this disease.<\/jats:p>","DOI":"10.1002\/cpt.1202","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T17:03:51Z","timestamp":1541783031000},"page":"1042-1046","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Battling the <scp>HIV<\/scp>\/<scp>AIDS<\/scp> Epidemic: Triumphs and Barriers"],"prefix":"10.1111","volume":"104","author":[{"given":"Eliza R.","family":"McColl","sequence":"first","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dea","family":"Kojovic","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micheline","family":"Piquette\u2010Miller","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3132"},{"key":"e_1_2_8_2_1","unstructured":"UNAIDS.Fact Sheet \u2013 Latest Global HIV Statistics. <http:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDS_FactSheet_en.pdf> (2018). Accessed 26 July 2018."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130254"},{"key":"e_1_2_8_4_1","first-page":"45","article-title":"Strategies to improve HIV treatment adherence in developed countries: clinical management at the individual level","volume":"3","author":"Enriquez M.","year":"2011","journal-title":"HIV AIDS (Auckl.)"},{"key":"e_1_2_8_5_1","unstructured":"World Health Organization.Updated recommendations on first\u2010line and second\u2010line antiretroviral regimens and post\u2010exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. <http:\/\/www.who.int\/hiv\/pub\/guidelines\/ARV2018update\/en\/> (2018). Accessed 26 July 2018."},{"key":"e_1_2_8_6_1","unstructured":"Food and Drug Administration.Highlights of Prescribing Information: TROGARZO\u2122 (ibalizumab\u2010uiyk) injection. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761065lbl.pdf> (2018). Accessed 26 July 2018."},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1208"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1212"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1227"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1172"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-2197-0"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1201"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3152"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1221"},{"key":"e_1_2_8_15_1","unstructured":"HIV.gov.Data & trends: U.S. statistics. <https:\/\/www.hiv.gov\/hiv-basics\/overview\/data-and-trends\/statistics> (2018). Accessed 26 July 2018."},{"key":"e_1_2_8_16_1","unstructured":"Dreamspartnership.org.About dreams. <http:\/\/www.dreamspartnership.org\/aboutdreams\/#what-we-do> (2018). Accessed 26 July 2018."}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1202","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:35:53Z","timestamp":1699364153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1002\/cpt.1202"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1202","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"2018-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}